MOVANTIK

Peak

naloxegol oxalate

NDAORALTABLET
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

mu-opioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in tissues, such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone…

Indications (3)

opioid-induced constipation (OIC) in adult patients with chronic non-cancer painincluding patients with chronic pain related to prior cancerits treatment

Clinical Trials (2)

NCT03060512Phase 4Completed

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

Started Mar 2017
276 enrolled
Opioid Induced Constipation
NCT02998606Phase 2Terminated

Movantik for Opioid-Related Esophageal Disorders

Started Jan 2017
2 enrolled
Opioid-Induced DisordersEsophagus Disorder

Loss of Exclusivity

LOE Date
Apr 2, 2032
73 months away
Patent Expiry
Apr 2, 2032

Patent Records (2)

Patent #ExpiryTypeUse Code
7786133
Sep 16, 2028
SubstanceProduct
—
9012469
Apr 2, 2032
SubstanceProduct
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers